1
|
Qian X, Chen C, Tong S, Zhang J. Circ_MACF1 targets miR-421 to upregulate FMO2 to suppress paclitaxel resistance and malignant cellular behaviors in lung adenocarcinoma. Thorac Cancer 2023; 14:3348-3357. [PMID: 37814902 PMCID: PMC10665787 DOI: 10.1111/1759-7714.15132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 09/22/2023] [Accepted: 09/25/2023] [Indexed: 10/11/2023] Open
Abstract
BACKGROUND Chemoresistance remains an enormous challenge in the treatment of lung adenocarcinoma (LADC). Circular RNAs (circRNAs) exhibit important regulation in tumor progression and chemoresistance. This research focused on exploring the regulatory function and mechanism of circ_MACF1 (has_circ_0011780) in paclitaxel (PTX) resistance in LADC. METHODS Circ_MACF1, miR-421 and flavin-containing monooxygenase 2 (FMO2) were determined by RT-qPCR. MTT was applied to detect IC50 of PTX. The proliferation analysis was performed using EdU and colony formation assay. Cell apoptosis and motility were examined using flow cytometry and transwell assay, respectively. Western blot was administered for protein detection. A dual-luciferase reporter assay was performed for confirming target interaction. PTX sensitivity in vivo was researched via xenograft tumor assay. RESULTS Expression of circ_MACF1 was decreased in PTX-resistant LADC tissues and cells. Circ_MACF1 overexpression reduced chemoresistance, proliferation, motility and accelerated apoptosis in PTX-resistant LADC cells. Circ_MACF1 targeted miR-421 and miR-421 upregulation reverted circ_MACF1-evoked effects. FMO2 served as a downstream target of miR-421 and circ_MACF1 sponged miR-421 to elevate the expression of FMO2. MiR-421 enhanced PTX resistance and LADC progression via targeting FMO2. FMO2 knockdown enhanced IC50 of PTX and cell proliferation. In vivo, circ_MACF1 elevated PTX sensitivity of LADC by mediating miR-421/FMO2 axis. CONCLUSION These findings elucidated that circ_MACF1 inhibited PTX resistance by absorbing miR-421 to upregulate FMO2 in LADC.
Collapse
Affiliation(s)
- Xiaoting Qian
- Department of Pharmacy, Chun'an First People's HospitalZhejiang Provincial People's Hospital (Chun'an Branch)ZhejiangChina
| | - Chunhua Chen
- Department of CardiologyChun'an First People's Hospital, Zhejiang Provincial People's Hospital (Chun'an Branch)ZhejiangChina
| | - Sanxiang Tong
- Department of Infectious DiseaseChun'an First People's Hospital, Zhejiang Provincial People's Hospital (Chun'an Branch)ZhejiangChina
| | - Jun Zhang
- Department of GastroenterologyZhejiang Provincial People's HospitalZhejiangChina
| |
Collapse
|
2
|
Abstract
Flavoenzymes are broadly employed as biocatalysts for a large variety of reactions, owing to the chemical versatility of the flavin cofactor. Oxidases set aside, many flavoenzymes require a source of electrons in form of the biological reductant nicotinamide NAD(P)H in order to initiate catalysis via the reduced flavin. Chemists can take advantage of the reactivity of reduced flavins with oxygen to carry out monooxygenation reactions, while the reduced flavin can also be used for formal hydrogenation reactions. The main advantage of these reactions compared to chemical approaches is the frequent regio-, chemo- and stereo-selectivity of the biocatalysts, which allows the synthesis of chiral molecules in optically active form. This chapter provides an overview of the variety of biocatalytic processes that have been developed with flavoenzymes, with a particular focus on nicotinamide-dependent enzymes. The diversity of molecules obtained is highlighted and in several cases, strategies that allow control of the stereochemical outcome of the reactions are reviewed.
Collapse
Affiliation(s)
- Mélanie Hall
- Department of Chemistry, University of Graz, Graz, Austria.
| |
Collapse
|
3
|
Wiltschi B, Cernava T, Dennig A, Galindo Casas M, Geier M, Gruber S, Haberbauer M, Heidinger P, Herrero Acero E, Kratzer R, Luley-Goedl C, Müller CA, Pitzer J, Ribitsch D, Sauer M, Schmölzer K, Schnitzhofer W, Sensen CW, Soh J, Steiner K, Winkler CK, Winkler M, Wriessnegger T. Enzymes revolutionize the bioproduction of value-added compounds: From enzyme discovery to special applications. Biotechnol Adv 2020; 40:107520. [DOI: 10.1016/j.biotechadv.2020.107520] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 10/18/2019] [Accepted: 01/13/2020] [Indexed: 12/11/2022]
|
4
|
Masuyama Y, Nishikawa M, Yasuda K, Sakaki T, Ikushiro S. Whole-cell dependent biosynthesis of N- and S-oxides using human flavin containing monooxygenases expressing budding yeast. Drug Metab Pharmacokinet 2020; 35:274-280. [PMID: 32305264 DOI: 10.1016/j.dmpk.2020.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 01/16/2020] [Accepted: 01/27/2020] [Indexed: 10/24/2022]
Abstract
Flavin containing monooxygenases (FMOs) represent one of the predominant types of phase I drug metabolizing enzymes (DMEs), and thus play an important role in the metabolism of xeno- and endobiotics for the generation of their corresponding oxides. These oxides often display biological activities, however they are difficult to study since their chemical or biological synthesis is generally challenging even though only small amounts are required to evaluate their efficacy and safety. Previously, we constructed a DME expression system for cytochrome P450, UDP-glucuronosyltransferase (UGT), and sulfotransferase (SULT) using yeast cells, and successfully produced xenobiotic metabolites in a whole-cell dependent manner. In this study, we developed a heterologous expression system for human FMOs, including FMO1-FMO5, in Saccharomyces cerevisiae and examined its N- and S-oxide productivity. The recombinant yeast cells expressed each of the FMO successfully, and the FMO4 transformant produced N- and S-oxide metabolites at several milligrams per liter within 24 h. This whole-cell dependent biosynthesis enabled the production of N- and S-oxides without the use of the expensive cofactor NADPH. Such novel yeast expression system could be a powerful tool for the production of oxide metabolites.
Collapse
Affiliation(s)
- Yuuka Masuyama
- Department of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama, 939-0398, Japan
| | - Miyu Nishikawa
- Department of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama, 939-0398, Japan
| | - Kaori Yasuda
- Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama, 939-0398, Japan
| | - Toshiyuki Sakaki
- Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama, 939-0398, Japan
| | - Shinichi Ikushiro
- Department of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama, 939-0398, Japan.
| |
Collapse
|
5
|
Catucci G, Gilardi G, Sadeghi SJ. Production of drug metabolites by human FMO3 in Escherichia coli. Microb Cell Fact 2020; 19:74. [PMID: 32197603 PMCID: PMC7085137 DOI: 10.1186/s12934-020-01332-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 03/13/2020] [Indexed: 11/17/2022] Open
Abstract
Background In the course of drug discovery and development process, sufficient reference standards of drug metabolites are required, especially for preclinical/clinical or new therapeutic drugs. Whole-cell synthesis of drug metabolites is of great interest due to its low cost, low environmental impact and specificity of the enzymatic reaction compared to chemical synthesis. Here, Escherichia coli (E. coli) JM109 cells over-expressing the recombinant human FMO3 (flavin-containing monooxygenase isoform 3) were used for the conversions of clomiphene, dasatinib, GSK5182 and tozasertib to their corresponding N-oxide metabolites. Results The effects of NADPH regeneration, organic solvents as well as C-terminal truncations of human FMO3 were investigated. Under the optimized conditions, in excess of 200 mg/L of N-oxide metabolite of each of the four drugs could be produced by whole-cell catalysis within 24 h. Of these, more than 90% yield conversions were obtained for the N-oxidation of clomiphene and dasatinib. In addition, FMO3 shows high regio-selectivity in metabolizing GSK5182 where only the (Z) isomer is monooxygenated. Conclusions The study shows the successful use of human FMO3-based whole-cell as a biocatalyst for the efficient synthesis of drug metabolites including regio-selective reactions involving GSK5182, a new candidate against type 2 diabetes mellitus.
Collapse
Affiliation(s)
- Gianluca Catucci
- Department of Life Sciences and Systems Biology, University of Torino, Via Accademia Albertina 13, 10123, Turin, Italy
| | - Gianfranco Gilardi
- Department of Life Sciences and Systems Biology, University of Torino, Via Accademia Albertina 13, 10123, Turin, Italy
| | - Sheila J Sadeghi
- Department of Life Sciences and Systems Biology, University of Torino, Via Accademia Albertina 13, 10123, Turin, Italy.
| |
Collapse
|
6
|
Ancestral-sequence reconstruction unveils the structural basis of function in mammalian FMOs. Nat Struct Mol Biol 2019; 27:14-24. [PMID: 31873300 DOI: 10.1038/s41594-019-0347-2] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Accepted: 11/01/2019] [Indexed: 02/02/2023]
Abstract
Flavin-containing monooxygenases (FMOs) are ubiquitous in all domains of life and metabolize a myriad of xenobiotics, including toxins, pesticides and drugs. However, despite their pharmacological importance, structural information remains bereft. To further our understanding behind their biochemistry and diversity, we used ancestral-sequence reconstruction, kinetic and crystallographic techniques to scrutinize three ancient mammalian FMOs: AncFMO2, AncFMO3-6 and AncFMO5. Remarkably, all AncFMOs could be crystallized and were structurally resolved between 2.7- and 3.2-Å resolution. These crystal structures depict the unprecedented topology of mammalian FMOs. Each employs extensive membrane-binding features and intricate substrate-profiling tunnel networks through a conspicuous membrane-adhering insertion. Furthermore, a glutamate-histidine switch is speculated to induce the distinctive Baeyer-Villiger oxidation activity of FMO5. The AncFMOs exhibited catalysis akin to human FMOs and, with sequence identities between 82% and 92%, represent excellent models. Our study demonstrates the power of ancestral-sequence reconstruction as a strategy for the crystallization of proteins.
Collapse
|
7
|
Gao C, Zheng T. Drug metabolite synthesis by immobilized human FMO3 and whole cell catalysts. Microb Cell Fact 2019; 18:133. [PMID: 31405378 PMCID: PMC6691536 DOI: 10.1186/s12934-019-1189-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Accepted: 08/07/2019] [Indexed: 12/26/2022] Open
Abstract
Background Sufficient reference standards of drug metabolites are required in the drug discovery and development process. However, such drug standards are often expensive or not commercially available. Chemical synthesis of drug metabolite is often difficulty due to the highly regio- and stereo-chemically demanding. The present work aims to construct stable and efficient biocatalysts for the generation of drug metabolites in vitro. Result In this work, using benzydamine as a model drug, two easy-to-perform approaches (whole cell catalysis and enzyme immobilization) were investigated for the synthesis of FMO3-generated drug metabolites. The whole cell catalysis was carried out by using cell suspensions of E. coli JM109 harboring FMO3 and E. coli BL21 harboring GDH (glucose dehydrogenase), giving 1.2 g/L benzydamine N-oxide within 9 h under the optimized conditions. While for another approach, two HisTrap HP columns respectively carrying His6-GDH and His6-FMO3 were connected in series used for the biocatalysis. In this case, 0.47 g/L benzydamine N-oxide was generated within 2.5 h under the optimized conditions. In addition, FMO3 immobilization at the C-terminal (membrane anchor region) significantly improved its enzymatic thermostability by more than 10 times. Moreover, the high efficiency of these two biocatalytic approaches was also confirmed by the N-oxidation of tamoxifen. Conclusions The results presented in this work provides new possibilities for the drug-metabolizing enzymes-mediated biocatalysis. Electronic supplementary material The online version of this article (10.1186/s12934-019-1189-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Chongliang Gao
- Department of Life Sciences and Systems Biology, University of Torino, Via Accademia Albertina 13, 10123, Turin, Italy.
| | - Tingjie Zheng
- Department of Life Sciences and Systems Biology, University of Torino, Via Accademia Albertina 13, 10123, Turin, Italy
| |
Collapse
|
8
|
Winkler M, Geier M, Hanlon SP, Nidetzky B, Glieder A. Human Enzymes for Organic Synthesis. Angew Chem Int Ed Engl 2018; 57:13406-13423. [PMID: 29600541 PMCID: PMC6334177 DOI: 10.1002/anie.201800678] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Indexed: 02/06/2023]
Abstract
Human enzymes have been widely studied in various disciplines. The number of reactions taking place in the human body is vast, and so is the number of potential catalysts for synthesis. Herein, we focus on the application of human enzymes that catalyze chemical reactions in course of the metabolism of drugs and xenobiotics. Some of these reactions have been explored on the preparative scale. The major field of application of human enzymes is currently drug development, where they are applied for the synthesis of drug metabolites.
Collapse
Affiliation(s)
- Margit Winkler
- Institute for Molecular BiotechnologyGraz University of TechnologyPetersgasse 148010GrazAustria
- acib GmbHPetersgasse 148010GrazAustria
| | | | | | - Bernd Nidetzky
- acib GmbHPetersgasse 148010GrazAustria
- Institute of Biotechnology and Biochemical EngineeringGraz University of TechnologyPetersgasse 128010GrazAustria
| | - Anton Glieder
- Institute for Molecular BiotechnologyGraz University of TechnologyPetersgasse 148010GrazAustria
| |
Collapse
|
9
|
Salter R, Beshore DC, Colletti SL, Evans L, Gong Y, Helmy R, Liu Y, Maciolek CM, Martin G, Pajkovic N, Phipps R, Small J, Steele J, de Vries R, Williams H, Martin IJ. Microbial biotransformation – an important tool for the study of drug metabolism. Xenobiotica 2018; 49:877-886. [DOI: 10.1080/00498254.2018.1512018] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Rhys Salter
- Department of Preclinical Development and Safety, Janssen Research and Development LLC, Spring House, PA, USA
| | | | | | | | - Yong Gong
- Department of Preclinical Development and Safety, Janssen Research and Development LLC, Spring House, PA, USA
| | - Roy Helmy
- Department of Pharmacokinetics, Pharmacokinetics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Yong Liu
- Department of Preclinical Development, Merck & Co., Inc., West Point, PA, USA
| | - Cheri M. Maciolek
- Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., West Point, PA, USA
| | - Gary Martin
- Department of Global Chemistry, Merck & Co., Inc., Rahway, NJ, USA
| | - Natasa Pajkovic
- Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., West Point, PA, USA
| | | | - James Small
- Department of Global Chemistry, Merck & Co., Inc., West Point, PA, USA
| | | | - Ronald de Vries
- Department of Preclinical Development and Safety, Janssen Pharmaceutica, Beerse, Belgium
| | | | - Iain J. Martin
- Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Boston, MA, USA
| |
Collapse
|
10
|
Winkler M, Geier M, Hanlon SP, Nidetzky B, Glieder A. Humane Enzyme für die organische Synthese. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201800678] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Margit Winkler
- Institut für Molekulare Biotechnologie; Technische Universität Graz; Petersgasse 14 8010 Graz Österreich
- acib GmbH; Petersgasse 14 8010 Graz Österreich
| | | | | | - Bernd Nidetzky
- acib GmbH; Petersgasse 14 8010 Graz Österreich
- Institut für Biotechnologie und Bioprozesstechnik; Technische Universität Graz; Petersgasse 12 8010 Graz Österreich
| | - Anton Glieder
- Institut für Molekulare Biotechnologie; Technische Universität Graz; Petersgasse 14 8010 Graz Österreich
| |
Collapse
|
11
|
Yilmaz Y, Williams G, Manevski N, Walles M, Krähenbühl S, Camenisch G. Functional assessment of rat pulmonary flavin-containing monooxygenase activity. Xenobiotica 2018; 49:503-512. [PMID: 29694257 DOI: 10.1080/00498254.2018.1469804] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The expression of flavin-containing monooxygenase (FMO) varies extensively between human and commonly used preclinical species such as rat and mouse. The aim of this study was to investigate the pulmonary FMO activity in rat using benzydamine. Furthermore, the contribution of rat lung to the clearance of benzydamine was investigated using an in vivo pulmonary extraction model. Benzydamine N-oxygenation was observed in lung microsomes and lung slices. Thermal inactivation of FMO and CYP inhibition suggested that rat pulmonary N-oxygenation is predominantly FMO mediated while any contribution from CYPs is negligible. The predicted lung clearance (CLlung) estimated from microsomes and slices was 16 ± 0.6 and 2.1 ± 0.3 mL/min/kg, respectively. The results from in vivo pulmonary extraction indicated no pulmonary extraction following intravenous and intra-arterial dosing to rats. Interestingly, the predicted CLlung using rat lung microsomes corresponded to approximately 35% of rat CLliver suggesting that the lung makes a smaller contribution to the whole body clearance of benzydamine. Although benzydamine clearance in rat appears to be predominantly mediated by hepatic metabolism, the data suggest that the lung may also make a smaller contribution to its whole body clearance.
Collapse
Affiliation(s)
- Yildiz Yilmaz
- a Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research , Basel , Switzerland
| | - Gareth Williams
- a Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research , Basel , Switzerland
| | - Nenad Manevski
- a Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research , Basel , Switzerland
| | - Markus Walles
- a Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research , Basel , Switzerland
| | - Stephan Krähenbühl
- b Clinical Pharmacology and Toxicology , University Hospital , Basel, Switzerland
| | - Gian Camenisch
- a Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research , Basel , Switzerland
| |
Collapse
|
12
|
Fiorentini F, Romero E, Fraaije MW, Faber K, Hall M, Mattevi A. Baeyer-Villiger Monooxygenase FMO5 as Entry Point in Drug Metabolism. ACS Chem Biol 2017; 12:2379-2387. [PMID: 28783300 DOI: 10.1021/acschembio.7b00470] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Flavin-containing monooxygenases (FMOs) are emerging as effective players in oxidative drug metabolism. Until recently, the functions of the five human FMO isoforms were mostly linked to their capability of oxygenating molecules containing soft N- and S-nucleophiles. However, the human FMO isoform 5 was recently shown to feature an atypical activity as Baeyer-Villiger monooxygenase. With the aim of evaluating such an alternative entry point in the metabolism of active pharmaceutical ingredients, we selected and tested drug molecules bearing a carbonyl group on an aliphatic chain. Nabumetone and pentoxifylline, two widely used pharmaceuticals, were thereby demonstrated to be efficiently oxidized in vitro by FMO5 to the corresponding acetate esters with high selectivity. The proposed pathways explain the formation of a predominant plasma metabolite of pentoxifylline as well as the crucial transformation of the pro-drug nabumetone into the pharmacologically active compound. Using the recombinant enzyme, the ester derivatives of both drugs were obtained in milligram amounts, purified, and fully characterized. This protocol can potentially be extended to other FMO5 candidate substrates as it represents an effective and robust bench-ready platform applicable to API screening and metabolite synthesis.
Collapse
Affiliation(s)
- Filippo Fiorentini
- Austrian
Centre of Industrial Biotechnology, c/o Department of Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria
- Department
of Biology and Biotechnology, University of Pavia, via Ferrata
9, 27100 Pavia, Italy
| | - Elvira Romero
- Molecular
Enzymology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, 9747
AG, Groningen, Netherlands
| | - Marco W. Fraaije
- Molecular
Enzymology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, 9747
AG, Groningen, Netherlands
| | - Kurt Faber
- Department
of Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria
| | - Mélanie Hall
- Department
of Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria
| | - Andrea Mattevi
- Austrian
Centre of Industrial Biotechnology, c/o Department of Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria
| |
Collapse
|
13
|
Jones BC, Srivastava A, Colclough N, Wilson J, Reddy VP, Amberntsson S, Li D. An Investigation into the Prediction of in Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates. Drug Metab Dispos 2017; 45:1060-1067. [PMID: 28784689 DOI: 10.1124/dmd.117.077396] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Accepted: 08/04/2017] [Indexed: 11/22/2022] Open
Abstract
Flavin-containing monooxygenases (FMO) are metabolic enzymes mediating the oxygenation of nucleophilic atoms such as nitrogen, sulfur, phosphorus, and selenium. These enzymes share similar properties to the cytochrome P450 system but can be differentiated through heat inactivation and selective substrate inhibition by methimazole. This study investigated 10 compounds with varying degrees of FMO involvement to determine the nature of the correlation between human in vitro and in vivo unbound intrinsic clearance. To confirm and quantify the extent of FMO involvement six of the compounds were investigated in human liver microsomal (HLM) in vitro assays using heat inactivation and methimazole substrate inhibition. Under these conditions FMO contribution varied from 21% (imipramine) to 96% (itopride). Human hepatocyte and HLM intrinsic clearance (CLint) data were scaled using standard methods to determine the predicted unbound intrinsic clearance (predicted CLint u) for each compound. This was compared with observed unbound intrinsic clearance (observed CLint u) values back calculated from human pharmacokinetic studies. A good correlation was observed between the predicted and observed CLint u using hepatocytes (R2 = 0.69), with 8 of the 10 compounds investigated within or close to a factor of 2. For HLM the in vitro-in vivo correlation was maintained (R2 = 0.84) but the accuracy was reduced with only 3 out of 10 compounds falling within, or close to, twofold. This study demonstrates that human hepatocytes and HLM can be used with standard scaling approaches to predict the human in vivo clearance for FMO substrates.
Collapse
Affiliation(s)
- Barry C Jones
- Oncology IMED, Astrazeneca, Cambridge, United Kingdom (B.C.J., N.C., J.W., V.P.R.), DSM Astrazeneca, Cambridge, United Kingdom (A.S.); DSM Astrazeneca, Gothenburg, Sweden (S.A.); and Pharmaron, Beijing, China (D.L.)
| | - Abhishek Srivastava
- Oncology IMED, Astrazeneca, Cambridge, United Kingdom (B.C.J., N.C., J.W., V.P.R.), DSM Astrazeneca, Cambridge, United Kingdom (A.S.); DSM Astrazeneca, Gothenburg, Sweden (S.A.); and Pharmaron, Beijing, China (D.L.)
| | - Nicola Colclough
- Oncology IMED, Astrazeneca, Cambridge, United Kingdom (B.C.J., N.C., J.W., V.P.R.), DSM Astrazeneca, Cambridge, United Kingdom (A.S.); DSM Astrazeneca, Gothenburg, Sweden (S.A.); and Pharmaron, Beijing, China (D.L.)
| | - Joanne Wilson
- Oncology IMED, Astrazeneca, Cambridge, United Kingdom (B.C.J., N.C., J.W., V.P.R.), DSM Astrazeneca, Cambridge, United Kingdom (A.S.); DSM Astrazeneca, Gothenburg, Sweden (S.A.); and Pharmaron, Beijing, China (D.L.)
| | - Venkatesh Pilla Reddy
- Oncology IMED, Astrazeneca, Cambridge, United Kingdom (B.C.J., N.C., J.W., V.P.R.), DSM Astrazeneca, Cambridge, United Kingdom (A.S.); DSM Astrazeneca, Gothenburg, Sweden (S.A.); and Pharmaron, Beijing, China (D.L.)
| | - Sara Amberntsson
- Oncology IMED, Astrazeneca, Cambridge, United Kingdom (B.C.J., N.C., J.W., V.P.R.), DSM Astrazeneca, Cambridge, United Kingdom (A.S.); DSM Astrazeneca, Gothenburg, Sweden (S.A.); and Pharmaron, Beijing, China (D.L.)
| | - Danxi Li
- Oncology IMED, Astrazeneca, Cambridge, United Kingdom (B.C.J., N.C., J.W., V.P.R.), DSM Astrazeneca, Cambridge, United Kingdom (A.S.); DSM Astrazeneca, Gothenburg, Sweden (S.A.); and Pharmaron, Beijing, China (D.L.)
| |
Collapse
|
14
|
Fiorentini F, Geier M, Binda C, Winkler M, Faber K, Hall M, Mattevi A. Biocatalytic Characterization of Human FMO5: Unearthing Baeyer-Villiger Reactions in Humans. ACS Chem Biol 2016; 11:1039-48. [PMID: 26771671 DOI: 10.1021/acschembio.5b01016] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Flavin-containing mono-oxygenases are known as potent drug-metabolizing enzymes, providing complementary functions to the well-investigated cytochrome P450 mono-oxygenases. While human FMO isoforms are typically involved in the oxidation of soft nucleophiles, the biocatalytic activity of human FMO5 (along its physiological role) has long remained unexplored. In this study, we demonstrate the atypical in vitro activity of human FMO5 as a Baeyer-Villiger mono-oxygenase on a broad range of substrates, revealing the first example to date of a human protein catalyzing such reactions. The isolated and purified protein was active on diverse carbonyl compounds, whereas soft nucleophiles were mostly non- or poorly reactive. The absence of the typical characteristic sequence motifs sets human FMO5 apart from all characterized Baeyer-Villiger mono-oxygenases so far. These findings open new perspectives in human oxidative metabolism.
Collapse
Affiliation(s)
- Filippo Fiorentini
- Department
of Biology and Biotechnology, University of Pavia, via Ferrata
9, 27100 Pavia, Italy
- Austrian
Centre of Industrial Biotechnology, c/o Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
| | - Martina Geier
- Austrian
Centre of Industrial Biotechnology, c/o Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
| | - Claudia Binda
- Department
of Biology and Biotechnology, University of Pavia, via Ferrata
9, 27100 Pavia, Italy
| | - Margit Winkler
- Austrian
Centre of Industrial Biotechnology, c/o Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
| | - Kurt Faber
- Department
of Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria
| | - Mélanie Hall
- Department
of Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria
| | - Andrea Mattevi
- Department
of Biology and Biotechnology, University of Pavia, via Ferrata
9, 27100 Pavia, Italy
| |
Collapse
|
15
|
Gul T, Krzek M, Permentier HP, Fraaije MW, Bischoff R. Microbial Flavoprotein Monooxygenases as Mimics of Mammalian Flavin-Containing Monooxygenases for the Enantioselective Preparation of Drug Metabolites. Drug Metab Dispos 2016; 44:1270-6. [DOI: 10.1124/dmd.115.069104] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 03/15/2016] [Indexed: 12/27/2022] Open
|